Loading
Tepotinib is a once-daily targeted pill for lung cancers driven by a MET exon 14 skipping mutation, and the MET inhibitor NICE funds in England.
Tepotinib is an oral MET inhibitor for advanced non-small cell lung cancer with MET exon 14 skipping alterations, which can be detected in tumour tissue or in circulating tumour DNA. The VISION trial showed durable responses in about half of patients whether or not they had been treated before. Japan approved it first in 2020, the FDA in 2021 and the EU in 2022. NICE recommended it in 2022 within its licence with a commercial arrangement. Peripheral oedema is the main side effect.
A highly selective, once-daily MET kinase inhibitor that blocks signalling from MET receptors kept active by exon 14 skipping mutations. Connects to MET.
1.Tepotinib slips into a pocket on MET.
Sources: NICE TA789. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
Treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
Accelerated approval on a surrogate endpoint, with a confirmatory trial required.
Treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
Confirmed: the accelerated approval of 2021 converted to traditional approval 3.0 years after it was granted.
| Region | Year | Indication |
|---|---|---|
| US | 2021 | Metastatic NSCLC with MET exon 14 skipping alterations |
| EU | 2022 | Advanced NSCLC with MET exon 14 skipping alterations after immunotherapy or platinum chemotherapy |
| JP | 2020 | Unresectable advanced or recurrent NSCLC with MET exon 14 skipping |
| England (NICE) | 2022 | Advanced non-small-cell lung cancer with MET exon 14 skipping alterations · TA789, published 18 May 2022, subject to the commercial arrangement (VISION). |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
A rare driver with a real drug, and a warning about biomarker thresholds: the same gene, tested the same way, predicts response or does not depending on a copy-number cut-off that has to be measured rather than assumed.
Tepotinib is an approved alternative to capmatinib for MET exon 14 lung cancer, and the trial validated circulating tumour DNA as a way to find the alteration.
It made MET exon 14 a clinical entity rather than a sequencing curiosity, and identified the patients most likely to be missed: older people whose age would otherwise argue against broad sequencing.
Query for this drug: (TITLE:"Tepotinib" OR ABSTRACT:"Tepotinib" OR TITLE:"Tepmetko" OR ABSTRACT:"Tepmetko" OR TITLE:"MSC2156119" OR ABSTRACT:"MSC2156119" OR TITLE:"EMD 1214063" OR ABSTRACT:"EMD 1214063") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Tepotinib, not a curated reading list.
Shares MET exon 14 skipping mutation, MET exon 14 skipping mutation, Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer, MET exon 14 and MET-amplified non-small-cell lung cancer.
Shares VISION (tepotinib), MET exon 14 skipping mutation, Merck KGaA (EMD Serono), MET exon 14 and MET-amplified non-small-cell lung cancer.
Shares MET exon 14 skipping mutation, MET amplification (gene copy number), MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression, MET.
Shares Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer, Capmatinib, MET exon 14 and MET-amplified non-small-cell lung cancer, MET.
Shares MET amplification (gene copy number), MET exon 14 skipping mutation, MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression, MET exon 14 and MET-amplified non-small-cell lung cancer.
Shares VISION: tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations, MET exon 14 and MET-amplified non-small-cell lung cancer, Lung cancer (all types), Non-small-cell lung cancer.
Shares MET amplification (gene copy number), MET exon 14 skipping mutation, MET exon 14 and MET-amplified non-small-cell lung cancer, MET.
Shares Sarcomatoid carcinoma of the lung, MET exon 14 skipping mutation, MET exon 14 and MET-amplified non-small-cell lung cancer, MET.